Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

hat the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, the Novartis Group offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. The Novartis Group is the only company with leading positions in each of these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

References

  1. Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem ce
    '/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... New York City. The public is welcome to participate ... Array BioPharma website.Event: Jefferies 2015 Global Healthcare ConferencePresenter:Ron ... Eastern Time Webcast: www.arraybiopharma.com  About Array BioPharma ...
(Date:5/26/2015)... May 26, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that Steven A. Kriegsman , ... , Vice President of Business Development and Investor Relations, ... Global Healthcare Conference on Tuesday, June 2, 2015 at ... at the Grand Hyatt in New York, ...
(Date:5/26/2015)... , May 26, 2015 Sanomedics, Inc. (OTC: ... it has expanded into the fast growing behavioral health ... Charts is a developmental stage, Software as a Services ... on addiction treatment service and care centers. ... Sanomedics to enter the nascent behavioral health sector where ...
Breaking Medicine Technology:CytRx to Present at the Jefferies 2015 Global Healthcare Conference 2Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 2Sanomedics Targeting Behavioral Health and Electronic Health Records with Strategic Acquisition of Zen Charts 3
... , LAKE ZURICH, Ill., Dec. 15 Fenwal ... safety and availability for patient care, reiterated its commitment ... to collect lifesaving blood products, despite a new lawsuit ... The Fenwal® Alyx® system, introduced in 2003, is ...
... BALTIMORE, Dec. 15 Champions Biotechnology, Inc . (OTC ... advanced preclinical platforms and tumor specific data to enhance the ... the second fiscal quarter ended October 31, 2009. Full ... Form 10-Q at www.championsbiotechnology.com . , Total revenues for ...
Cached Medicine Technology:Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5
(Date:5/26/2015)... Last week, Carlsbad Open MRI—a medical ... Ultrasound, and CT services—was officially awarded ACR accreditation ... The center is now ACR accredited for both ... to be eligible for ACR accreditation, facilities are ... qualifications, adequacy of facility equipment, quality control procedures, ...
(Date:5/26/2015)... 26, 2015 Sexual harassment and sexual assault ... is best known for creating opportunities in women's athletics, it ... assault response and prevention. In a recent episode of ... Advocates explains what Title IX means for university administrators ... front of this issue to protect students. , In the ...
(Date:5/26/2015)... 26, 2015 Abington is pleased ... a physician practice with seven medical professionals, has ... eighth primary-care site in the United States to ... home by the National Committee for Quality Assurance. ... preventative and sick care – including routine gynecology ...
(Date:5/26/2015)... Tysons Corner, VA (PRWEB) May 26, 2015 ... mission critical technology and management consulting solutions to the ... of Technology Strategy and Cloud Solutions. In this newly ... firm’s strategic capabilities and growth in cloud computing, big ... GP join our expanding leadership team as we continue ...
(Date:5/26/2015)... On May 26, 2015, My Positive Perspective host Jason ... Windfall. At the start of the episode, Deierlein asks Windfall, ... characteristics with it, so could you tell people how you ... was reading the newspaper looking for a job when I ... a person with hustle. I responded to the ad and ...
Breaking Medicine News(10 mins):Health News:Paul Greene Explores Title IX and College Sports on SCI TV 2Health News:Paul Greene Explores Title IX and College Sports on SCI TV 3Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:My Positive Perspective Broadcasts Episode with Oceans 6 to Discuss Their Role in Helping the Community 2
... deadly H5N1 strain of bird flu has been detected in ... African// country to be hit by bird flu. ... several cases have gone unnoticed. Currently 14 of Nigeria's 36 ... poultry. "We have identified it in three places in Taraba, ...
... method to reform the mandible (lower jaw) of oral cancer ... Eric Moore, M.D., said that without reconstructive procedures difficulties such ... in mandible-removed oral cancer patients. ,‘We think this ... a good tool for reconstructive surgeons,’ says Daniel Price, M.D., ...
... While some progress has been taken to improve the ... to be investigated - Researchers team reported// in an ... eight countries including Australia, China, Finland, Ireland, Japan, Kuwait, ... the International Association for Dental Research that more work ...
... at improving women's health researchers are facing a major ... participation in food trials and studies. ,Food ... lack of available women's research at this week's Institute ... world's largest annual meeting on food science, business and ...
... A pick-up game of basketball often leaves you with a ... would most likely leave you feeling a little dizzy and ... you? ,Dizziness and nausea are two signs of ... head athletic trainer and instructor at the University of Indianapolis. ...
... the Department of Energy's Pacific Northwest National Laboratory and ... damage in neurodegenerative diseases// is linked to a natural ... Parkinson's, Alzheimer's, Lou Gehrig's disease and other brain disorders ... in health conditions that can be credited to oxidative ...
Cached Medicine News:Health News:Jaw Reconstruction could be Possible in Oral Cancer Patients 2Health News:Jaw Reconstruction could be Possible in Oral Cancer Patients 3Health News:Unhealthy Oral Habits among Teenagers – Reported Dental Health Authoritie 2Health News:Women Doubtful of Food Research Benefiting Them 2Health News:Scientist Optimistic In Breakthrough For Causes Of Neurodegenerative Diseases 2
Built-in convexity means added security and skin protection for recessed, retracted and flush stomas...pre-cut openings. Security and confidence achieved by the internal No-Flowback Valves and soft d...
Inquire...
Inquire...
Inquire...
Medicine Products: